The data are useful for predicting the efficacy of Ara-C in individual malignant tumors, as heterozygous mutations in the exonuclease domain of Polε account for ~10% of colorectal cancer and endometrial cancer [36, 37]. The gene discussed is POLE; the disease is endometrial cancer.